doi:

DOI: 10.3724/SP.J.1005.2009.00683

Hereditas (Beijing) (遗传) 2009/31:7 PP.683-688

In vivo delivery of siRNA


Abstract:
RNA interference (RNAi) is a mechanism of posttranscriptional gene silencing mediated by small interfering RNA (siRNA). The ability of synthetic siRNA to silence genes in vivo has made it well suited as therapeutic drug, but the instability and polarity of siRNA and the complexity of in vivo circumstances retarded rapid development of RNAi-based therapies. In this review, a summary of the advances on in vivo siRNA delivery is presented and dis-cussed.

Key words:RNAi,siRNA,siRNA delivery

ReleaseDate:2014-07-21 14:39:25



[1] Aagaard L, Rossi JJ. RNAi therapeutics: principles, pros-pects and challenges.Adv Drug Deliv Rev, 2007, 59(2-3): 75-86.

[2] Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391(6669): 806-811.

[3] Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet, 2007, 8(3): 173-184.

[4] Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: An update on delivery. Curr Opin Mol Ther, 2008, 10(2): 158-167.

[5] Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432(7014): 173-178.

[6] Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest, 2007, 117(12): 3623-3632.

[7] Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 2005, 23(4): 457-462.

[8] Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cy-cle, 2006, 5(18): 2103-2109.

[9] Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncopro-tein p28GANK in hepatocellular carcinoma. Gastroen-terology, 2005, 128(7): 2029-2041.

[10] Gurzov EN, Izquierdo M. RNA interference against Hec1 in-hibits tumor growth in vivo. Gene Ther, 2006, 13(1): 1-7.

[11] Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res, 2005, 65(23): 10680-10685.

[12] Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther, 2005, 4 (10): 1577-1584.

[13] Tomar RS, Matta H, Chaudhary PM. Use of adeno-asso-ciated viral vector for delivery of small interfering RNA. Oncogene, 2003, 22(36): 5712-5715.

[14] Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, Mcintyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003, 348(3): 255-256.

[15] Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, Esposito G, Wagner R, Uberla K, Chieco- Bianchi L, Amadori A. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res, 2002, 62 (21): 6099-6107.

[16] Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, Helmchen F, Denk W, Brecht M, Osten P. Len-tivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc Natl Acad Sci USA, 2004, 101(52): 18206-18211.

[17] Bahi A, Boyer F, Kolira M, Dreyer JL. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem, 2005, 92(5): 1243-1255.

[18] An DS, Donahue RE, Kamata M, Poon B, Metzger M, Mao SH, Bonifacino A, Krouse AE, Darlix JL, Baltimore D, Qin FX, Chen IS. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA, 2007, 104(32): 13110-13115.

[19] Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA. Suppression of ocular neovascularization with siRNA tar- geting VEGF receptor 1Gene Ther, 2006, 13(3): 225-234.

[20] Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med, 2005, 11(1): 50-55.

[21] Thakker DR, Natt F, Hüsken D, Maier R, Müller M, van der Putten H, Hoyer D, Cryan JF. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA, 2004, 101(49): 17270-17275.

[22] de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther, 2008, 19(2): 125-132.

[23] Oliveira S, Storm G, Schiffelers RM. Targeted Delivery of siRNA. J Biomed Biotechnol, 2006, 2006(4): 63675.

[24] Lewis DL, Wolff JA. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev, 2007, 59(2-3): 115-123.

[25] Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol, 2007, 25(10): 1149-1157.

[26] McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 2006, 24(8): 1005-1015.

[27] Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. A novel siRNA-lipoplex technol-ogy for RNA interference in the mouse vascular endothe-lium. Gene Ther, 2006, 13(16): 1222-1234.

[28] Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. RNAi- me-diated gene silencing in non- human primates. Nature, 2006, 441(7089): 111-114.

[29] Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of neuropilin-2 on colo-rectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst, 2008, 100(2): 109-120.

[30] Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE, Wolff JA. Dynamic Poly Conjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA, 2007, 104(32): 12982-12987.

[31] Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res, 2005, 65(19): 8984-8992.

[32] Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med, 13(3): 372-377.

[33] Akhtar S, Benter I. Toxicogenomics of non-viral drug de-livery systems for RNAi: Potential impact on siRNA- me-diated gene silencing activity and specificity. Adv Drug Deliv Rev, 2007, 59(2-3):164-182.

[34] Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev, 2007, 59(2-3): 134-140.

[35] Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149): 39-43.

[36] Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo de-livery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 2005, 23(6): 709-717.

[37] Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Se-lective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated anti-gen-1. Proc Natl Acad Sci USA, 2007, 104(10): 4095-4100.

[38] Wen WH, Liu JY, Qin WJ, Zhao J, Wang T, Jia LT, Meng YL, Gao H, Xue CF, Jin BQ, Yao LB, Chen SY, Yang AG. Targeted inhibition of HBV gene expression by sin-gle-chain antibody mediated small interfering RNA deliv-ery. Hepatology, 2007, 46(1): 84-94.

[39] Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell, 2008, 134(4): 577-586.

[40] Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006, 441(7092): 537-541.

PDF